ArticleTherapeutic advances in respiratory disease
Early treatment burden predicts recurrence or progression after bronchoscopic intervention for infection- or injury-related benign airway stenosis: A two-center longitudinal cohort study.
Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundPatients with infection- or injury-related benign airway stenosis often require repeated bronchoscopic interventions, but evidence is limited on how early treatment patterns can guide follow-up and risk reassessment.ObjectivesTo derive phase-adapted surveillance windows after bronchoscopic intervention and determine whether the 24-week treatment trajectory identifies patients at increased risk of subsequent recurrence or progression.DesignTwo-center retrospective longitudinal cohort study.MethodsPatients treated between January 2019 and December 2024 were included if they had infection- or injury-related benign airway stenosis and did not receive stent or T-tube placement during follow-up. Adjacent bronchoscopic records separated by ≤1 week were merged into one treatment episode. Valid intervals were defined as adjacent records separated by >1 week with assessable recurrence/progression status. Risk strata were constructed using treatment episodes within 24 weeks and window-end airway control: low risk, 1-3 episodes with adequate control; intermediate risk, 4-5 episodes or 1-3 episodes with inadequate control; and high risk, ≥6 episodes. A 24-week landmark analysis evaluated subsequent composite events.ResultsOverall, 213 patients contributed 879 valid intervals. Data-informed surveillance windows were approximately 1 week in the early phase, 2-3 weeks in the mid and consolidation phases, and 4-5 weeks in the maintenance phase. Among 93 patients included in landmark analysis, post-landmark composite event proportions were 31.3%, 60.9%, and 80.6% in the low-, intermediate-, and high-risk groups, respectively (log-rank P<0.001). In multivariable Cox regression, the high-risk group had a significantly increased risk of composite events (HR=5.849, 95% CI 2.031-16.845, P=0.001), whereas the intermediate-risk group showed a non-significant trend (HR=2.514, 95% CI 0.920-6.871, P=0.072).ConclusionEarly treatment burden provides clinically meaningful risk stratification after bronchoscopic intervention for benign airway stenosis. Six or more treatment episodes within 24 weeks may identify a treatment-dependent high-risk phenotype requiring intensified surveillance and comprehensive reassessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.